BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 9570481)

  • 1. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
    Mankhetkorn S; Garnier-Suillerot A
    Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
    Mankhetkorn S; Teodori E; Garnier-Suillerot A
    Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
    Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
    Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells.
    Wielinga PR; Westerhoff HV; Lankelma J
    Eur J Biochem; 2000 Feb; 267(3):649-57. PubMed ID: 10651800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
    Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
    Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
    Pereira E; Tarasiuk J; Garnier-Suillerot A
    Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
    Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
    Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
    Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
    Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
    Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
    Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
    Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
    Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
    Hargrave RM; Davey MW; Davey RA; Kidman AD
    Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
    Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
    Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
    den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
    Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
    Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
    Mülder HS; Dekker H; Pinedo HM; Lankelma J
    Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
    Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
    Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.